The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.
about
Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitorsGut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutideDose Modification of Antidiabetic Agents in Patients with Type 2 Diabetes Mellitus and Heart Failure.Glucagon Like Peptide-1 (GLP-1) Modulates OVA-Induced Airway Inflammation and Mucus Secretion Involving a Protein Kinase A (PKA)-Dependent Nuclear Factor-κB (NF-κB) Signaling Pathway in Mice.GLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond.Extra-pancreatic effects of incretin-based therapies.GLP-1: benefits beyond pancreas.Potential side effects to GLP-1 agonists: understanding their safety and tolerability.Pharmacologic treatment of type 2 diabetes: injectable medications.Insulin degludec + liraglutide: a complementary combination.Hepatic functions of GLP-1 and its based drugs: current disputes and perspectives.Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus.An update on DPP-4 inhibitors in the management of type 2 diabetes.Exendin-4 Reverses Biochemical and Functional Alterations in the Blood-Brain and Blood-CSF Barriers in Diabetic Rats.Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes.The cardiometabolic benefits of glycine: Is glycine an 'antidote' to dietary fructose?Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes.GLP-1(28-36)amide, a Long Ignored Peptide Revisited.A Review on the Phytochemistry, Pharmacology, Pharmacokinetics and Toxicology of Geniposide, a Natural Product.Combination therapy with remote ischaemic conditioning and insulin or exenatide enhances infarct size limitation in pigs.Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month Retrospective Study.Brain GLP-1/IGF-1 Signaling and Autophagy Mediate Exendin-4 Protection Against Apoptosis in Type 2 Diabetic Rats.Acute effects of the glucagon-like peptide-1 receptor agonist, exenatide, on blood pressure and heart rate responses to intraduodenal glucose infusion in type 2 diabetes.Efficacy and safety of canagliflozin as add-on therapy to a glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week, open-label, phase IV study.Effects of exogenous glucagon-like peptide-1 on blood pressure, heart rate, gastric emptying, mesenteric blood flow and glycaemic responses to oral glucose in older individuals with normal glucose tolerance or type 2 diabetes.Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates kidney injury in murine models of obesity and diabetes mellitus.Cardiovascular outcomes and safety with antidiabetic drugsExendin‑4 reverses endothelial dysfunction in mice fed a high‑cholesterol diet by a GTP cyclohydrolase‑1/tetrahydrobiopterin pathway
P2860
Q27021870-FF4DCAC3-9ABB-4ABD-881B-C443E86BF454Q28081671-BE9F2508-1DC7-4896-992B-3FBF20B9F9F9Q33815573-5A5B8AA0-042E-4A5C-A701-FB2F2773EFE5Q36183922-99F2F32D-AB7B-4F2F-B3BB-8C95A36ACE8BQ36406821-78258415-59BD-4FDE-AC0E-3F46BCCB91ACQ38194069-E8C823B0-F463-4BB2-AD3B-2394CF468C91Q38238288-CA75BF05-DB43-4D1D-8F1D-22DC4FED52BCQ38286444-473070E1-D7A4-40B0-971C-8D996E3B42FAQ38388602-C8854545-EA7B-418F-84A7-F6D991B98808Q38916256-61CDBC9D-CCDE-49E9-A5DC-F9BE97C6ECE4Q38923365-7AA8C784-A483-40A3-8EF4-F92AC916083EQ38989517-5E335CAB-B357-4120-A34A-7766025F654EQ38997456-883D63FA-56B5-4A37-AA36-895D93F88AB1Q39959089-C237DA85-DA33-423C-AE0B-A62D0418A388Q40432883-CE423383-02F5-441B-A992-3AF0800155EAQ41816192-34B4FB50-4E9B-455A-8BC8-2232BDE0144BQ42371337-73A5F1A8-E502-4596-A313-A8D8966C2599Q43105364-D7923318-845A-4873-953C-7633932DAFD6Q46289886-A7F40C91-6CC6-4C67-A61D-0F9EB1CB9AA6Q47382878-E28F6815-CE8E-4BE5-8624-E5DC4F17CD08Q47594612-04490227-995F-4337-8D40-ACB6BD4D397EQ50963300-51F9BCF8-39FC-4A53-8E35-AC8CA1045068Q51017631-11D93852-B5B0-4D8C-B841-21E6D906C847Q51246665-203D6972-36CC-42A0-886D-83E65581C0F8Q53215510-638E5458-55AA-4DEA-905C-7C021E69D1FAQ55456375-B1D3A7A3-7E9E-40D6-AE41-11DB1117906CQ57164250-D2BA6FED-A8AB-46BE-87C4-516EF452DB4AQ58805576-F41B6E2C-BD7E-49D8-A401-E3D6F441F4D1
P2860
The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The extra-pancreatic effects o ...... l and central nervous systems.
@en
type
label
The extra-pancreatic effects o ...... l and central nervous systems.
@en
prefLabel
The extra-pancreatic effects o ...... l and central nervous systems.
@en
P2860
P356
P1476
The extra-pancreatic effects o ...... l and central nervous systems.
@en
P2093
P2860
P304
P356
10.1111/DOM.12251
P577
2014-01-16T00:00:00Z